Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.34 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.34 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.34 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18308905 | 0.83 | TRPV3 (0.47) | EPAS1POLBALDH1A1TRPV3LMNA | |
| SCHEMBL17031833 | 0.81 | MEN1 (0.43) | EPAS1POLBALDH1A1TRPV3LMNA | |
| SCHEMBL6869892 | 0.69 | EPAS1 (0.54) | EPAS1ALDH1A1ESPL1 | |
| SCHEMBL18307727 | 0.68 | SDHB (0.39) | SMN1; SMN2NR1H2 | |
| SCHEMBL17033097 | 0.68 | POLB (0.45) | EPAS1POLBALDH1A1TRPV3LMNA | |
| SCHEMBL17040433 | 0.68 | LMNA (0.42) | EPAS1POLBALDH1A1TRPV3LMNA | |
| SCHEMBL29602415 | 0.67 | EPAS1 (0.59) | EPAS1ALDH1A1NR1H2NR1H3 | |
| SCHEMBL28304035 | 0.67 | EPAS1 (0.59) | EPAS1ALDH1A1NR1H2NR1H3 | |
| SCHEMBL17031824 | 0.67 | USP28 (0.42) | ALDH1A1LMNANR1H2NR1H3 | |
| SCHEMBL28069902 | 0.66 | EPAS1 (0.56) | EPAS1ALDH1A1ESPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190144473-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144473-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C9 | EPAS1 1637/4885POLB 4098/4885SCN9A 2611/4885 |
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | EPAS1 1637/4885POLB 4098/4885SCN9A 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.